| Name | Title | Contact Details |
|---|
Founded in 1965, PathGroup offers the latest in sophisticated diagnostic services covering a full range of clinical and anatomic pathology testing, including the latest in molecular diagnostics. PathGroup employs more than 60 board-certified pathologists representing every sub-specialty. The company’s medical diagnostic services combined with its sophisticated web-based PathConnect order/entry system and reporting system provide clients with the highest level of specialty service available.
siParadigm is committed to create sustainable value by delivering outstanding services to our clients to help them meet the challenges of today’s changing healthcare environment. Our team is diligent in improving the quality of healthcare by providing the highest quality of laboratory testing and unmatched Turn-Around-Time (TAT). We will strive to meet these objectives by continuing to grow and adapt to consistently meet the needs of our patients, clients, and health system.
PROCEPT BioRobotics is a clinical-stage medical device company based in Silicon Valley. The Company has developed a disruptive surgical product for transurethral resection of prostate tissue – The AquaBeam® * – and other treatment and diagnostic applications. The AquaBeam is a personalized image-guided tissue removal system, which utilizes proprietary heat-free high-velocity waterjet technology to resect and remove a predetermined volume of tissue with precise and automated incisions conforming to the shape of the prostate.
Innovive, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.